CoChat

Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disease whose primary clinical manifestation is bilateral visual loss. Only a single therapy, idebenone, is approved in Europe for use in exceptional circumstances and no therapy is currently approved in the USA. LHON remains a disease with a high unmet medical need. This is a report of an open-label, single-center, dose-escalation study that evaluated the safety and tolerability of lenadogene nolparvovec in 15 subjects with LHON for up to 5 years following a single intravitreal injection at four dose levels. Subjects were enrolled sequentially in four cohorts followed by an additional cohort at the dose selected, and safety was assessed by an independent data safety monitoring board (DSMB) prior to any dose escalation. Overall, the treatment was well tolerated during the 5-year follow-up. No serious adverse events were considered related to treatment, no unexpected adverse events occurred, and no grade 3 or 4 Common Terminology Criteria for Adverse Events were reported. Anterior chamber inflammation and vitritis were mostly managed with topical steroids, and ocular inflammation was considered to be dose limiting by the DSMB based on the benefits/risks for the subjects. Analysis of the logarithm of the minimal angle of resolution (LogMAR) visual acuity in both treated and untreated eyes showed clinically relevant and durable improvements compared with baseline. Mean improvements of − 0.44 and − 0.49 LogMAR for treated and untreated eyes, respectively, were noted, with a mean (± standard deviation) final value of LogMAR + 1.96 ± 0.60 and + 1.65 ± 0.34, respectively, at 5 years post-treatment administration. For the six subjects treated with the optimal dose level (9 × 10 10 viral genomes [vg]/eye), the mean visual acuity improvement from baseline reached − 0.68 LogMAR for treated eyes and − 0.64 LogMAR for untreated eyes, with a mean final value of LogMAR + 1.77 ± 0.52 and + 1.78 ± 0.34, respectively. While there was a meaningful improvement in visual acuity for REVEAL subjects, the final visual acuity was less favorable than that seen in the two subsequent pivotal phase III studies in which subjects were treated earlier during the course of their disease. Lenadogene nolparvovec was well tolerated with a good safety profile during 5 years of follow-up and may offer meaningful lasting improvements in vision for this LHON population. EUDRACT N° 2013-001405-90.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40259-021-00468-9

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Disposition of subjects. DSMB data safety monitoring board, vg viral genomes
Fig. 1 Disposition of subjects. DSMB data safety monitoring board, vg viral genomesCC BY-NC · PubMed Central
Fig. 2 Mean LogMAR scores from baseline at each visit to year 5 for all treated eyes. Cohort 1: 9 × 109 vg/eye; cohort 2: 3 × 1010 vg/eye; cohorts 3 and 5: 9 × 1010 vg/eye; cohort 4: 1.8 × 1011 vg/eye. LogMAR logarithm of the minimal angle of resolution, vg viral genomes
Fig. 2 Mean LogMAR scores from baseline at each visit to year 5 for all treated eyes. Cohort 1: 9 × 109 vg/eye; cohort 2: 3 × 1010 vg/eye; cohorts 3 and 5: 9 × 1010 vg/eye; cohort 4: 1.8 × 1011 vg/eye. LogMAR logarithm of the minimal angle of resolution, vg viral genomesCC BY-NC · PubMed Central
Fig. 3 Mean change in LogMAR from baseline at each visit to year 5 for all treated eyes. Cohort 1: 9 × 109 vg/eye; cohort 2: 3 × 1010 vg/eye; cohorts 3 and 5: 9 × 1010 vg/eye; cohort 4: 1.8 × 1011 vg/eye. LogMAR logarithm of the minimal angle of resolution, vg viral genomes
Fig. 3 Mean change in LogMAR from baseline at each visit to year 5 for all treated eyes. Cohort 1: 9 × 109 vg/eye; cohort 2: 3 × 1010 vg/eye; cohorts 3 and 5: 9 × 1010 vg/eye; cohort 4: 1.8 × 1011 vg/eye. LogMAR logarithm of the minimal angle of resolution, vg viral genomesCC BY-NC · PubMed Central
Fig. 4 Mean LogMAR scores at each visit and for both treated and untreated eyes at the 9 × 1010 vg/eye dose. LogMAR logarithm of the minimal angle of resolution, vg viral genomes
Fig. 4 Mean LogMAR scores at each visit and for both treated and untreated eyes at the 9 × 1010 vg/eye dose. LogMAR logarithm of the minimal angle of resolution, vg viral genomesCC BY-NC · PubMed Central
Fig. 5 Mean change of LogMAR at each visit for both treated and untreated eyes at the 9 × 1010 vg/eye dose. LogMAR logarithm of the minimal angle of resolution, vg viral genomes
Fig. 5 Mean change of LogMAR at each visit for both treated and untreated eyes at the 9 × 1010 vg/eye dose. LogMAR logarithm of the minimal angle of resolution, vg viral genomesCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 51

Metadata

Authors
Vignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A.
Affiliations
  • Inserm (FR)
  • Centre National de la Recherche Scientifique (FR)
  • GenSight Biologics (France) (FR)
Corresponding author
Taiel, Magali
Venue
BioDrugs
Published
2021-02-10
Volume
35
Issue
2
Pages
201-214
ISSN
  • 1172-7039 (ISSN-L)
  • 1173-8804
  • 1179-190X
OpenAlex
W3128161654
Cited by
51
References
42
Citations by year
2026: 9 · 2025: 11 · 2024: 4 · 2023: 9 · 2022: 13 · 2021: 4
FWCI
6.73
Type
journal article
Language
en
Open access
Licence
Locations
  • BioDrugs (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
Funders
GenSight Biologics
Topics
  • Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Keywords
Leber's hereditary optic neuropathy, intravitreal gene therapy, mitochondrial disease, visual acuity, safety and tolerability, ocular inflammation, dose escalation, idebenone, blindness prevention, long-term follow-up, ocular adverse effects
MeSH terms
Europe, Humans, Mutation, Visual Fields, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study. https://app.cochat.ai/papers/10.1007/s40259-021-00468-9
The paper
Vignal-Clermont, C., Girmens, J.-F., Audo, I., Said, S. M., Errera, M.-H., Plaine, L., O’Shaughnessy, D., Taiel, M., & Sahel, J.-A. (2021). Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study. BioDrugs. https://doi.org/10.1007/s40259-021-00468-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.